Biomarin Pharmaceutical Inc Strategic Asset Allocation Index
Biomarin Pharmaceutical Inc strategic asset allocation index. Biomarin Pharmaceutical Inc (BMRN) has a Strategic Asset Allocation Index of 0.0% as of June 2026. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $6.32 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See BMRN net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Biomarin Pharmaceutical Inc (2000–2025)
Strategic asset allocation index of Biomarin Pharmaceutical Inc from 2000 to 2025. This chart shows how Biomarin Pharmaceutical Inc's Strategic Asset Allocation Index has evolved across 24 annual periods from 2000 to 2025. As of June 2026, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $6.32 Billion USD. Check BMRN goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Biomarin Pharmaceutical Inc Strategic Asset Allocation Index by Year (2000–2025)
Biomarin Pharmaceutical Inc strategic asset allocation index by year from 2000 to 2025. The table below presents the year-by-year Strategic Asset Allocation Index for Biomarin Pharmaceutical Inc from 2000 to 2025, covering 24 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see BMRN market cap overview.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 8.1% | $492.24 Million | $- | $492.24 Million | $6.09 Billion | ▼ -1.1 pp |
| 2024 | 9.2% | $521.24 Million | $- | $521.24 Million | $5.66 Billion | ▼ -3.1 pp |
| 2023 | 12.3% | $611.13 Million | $- | $611.13 Million | $4.95 Billion | ▼ -19.1 pp |
| 2022 | 31.5% | $1.45 Billion | $1.11 Billion | $333.83 Million | $4.60 Billion | ▼ -4.7 pp |
| 2021 | 36.1% | $1.54 Billion | $1.04 Billion | $507.79 Million | $4.27 Billion | ▲ +4.0 pp |
| 2020 | 32.1% | $1.32 Billion | $1.03 Billion | $285.47 Million | $4.11 Billion | ▼ -13.5 pp |
| 2019 | 45.6% | $1.42 Billion | $1.01 Billion | $411.98 Million | $3.12 Billion | ▲ +5.7 pp |
| 2018 | 39.9% | $1.18 Billion | $948.68 Million | $235.86 Million | $2.97 Billion | ▼ -5.8 pp |
| 2017 | 45.7% | $1.28 Billion | $896.70 Million | $385.79 Million | $2.81 Billion | ▼ -3.9 pp |
| 2016 | 49.6% | $1.37 Billion | $798.77 Million | $572.71 Million | $2.77 Billion | ▲ +1.8 pp |
| 2015 | 47.8% | $1.15 Billion | $704.21 Million | $443.71 Million | $2.40 Billion | ▲ +7.1 pp |
| 2014 | 40.7% | $622.41 Million | $523.52 Million | $98.89 Million | $1.53 Billion | ▼ -3.1 pp |
| 2013 | 43.8% | $587.83 Million | $319.32 Million | $268.52 Million | $1.34 Billion | ▲ +4.3 pp |
| 2012 | 39.5% | $401.55 Million | $284.47 Million | $117.07 Million | $1.02 Billion | ▼ -7.5 pp |
| 2011 | 47.1% | $363.92 Million | $268.97 Million | $94.94 Million | $773.05 Million | ▼ -1.9 pp |
| 2010 | 49.0% | $351.12 Million | $221.87 Million | $129.25 Million | $717.26 Million | ▼ -12.9 pp |
| 2009 | 61.8% | $199.14 Million | $199.14 Million | $- | $322.19 Million | ▲ +16.6 pp |
| 2008 | 45.2% | $124.98 Million | $124.98 Million | $- | $276.68 Million | ▲ +4.3 pp |
| 2007 | 40.9% | $76.82 Million | $76.82 Million | $- | $187.73 Million | ▼ -6.2 pp |
| 2006 | 47.1% | $55.47 Million | $55.47 Million | $- | $117.80 Million | ▲ +25.7 pp |
| 2003 | 21.3% | $25.15 Million | $25.15 Million | $- | $117.85 Million | ▼ -7.3 pp |
| 2002 | 28.6% | $28.21 Million | $28.21 Million | $- | $98.54 Million | ▲ +8.2 pp |
| 2001 | 20.4% | $32.56 Million | $32.56 Million | $- | $159.55 Million | ▼ -9.2 pp |
| 2000 | 29.6% | $20.71 Million | $20.71 Million | $- | $69.99 Million | — |